vs
Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and CAMDEN NATIONAL CORP (CAC). Click either name above to swap in a different company.
Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $64.3M, roughly 1.2× CAMDEN NATIONAL CORP). CAMDEN NATIONAL CORP runs the higher net margin — 34.0% vs -9.6%, a 43.6% gap on every dollar of revenue. Over the past eight quarters, CAMDEN NATIONAL CORP's revenue compounded faster (22.6% CAGR vs -8.4%).
Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
BIOX vs CAC — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $77.6M | $64.3M |
| Net Profit | $-7.4M | $21.9M |
| Gross Margin | 46.8% | — |
| Operating Margin | 9.3% | — |
| Net Margin | -9.6% | 34.0% |
| Revenue YoY | -16.8% | — |
| Net Profit YoY | -20.2% | — |
| EPS (diluted) | $-0.12 | $1.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $64.3M | ||
| Q4 25 | — | $68.1M | ||
| Q3 25 | $77.6M | $65.4M | ||
| Q2 25 | — | $62.3M | ||
| Q1 25 | $60.6M | $60.1M | ||
| Q4 24 | $98.8M | $47.6M | ||
| Q3 24 | $93.3M | $45.0M | ||
| Q2 24 | — | $42.8M |
| Q1 26 | — | $21.9M | ||
| Q4 25 | — | $22.6M | ||
| Q3 25 | $-7.4M | $21.2M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | $-1.6M | $7.3M | ||
| Q4 24 | $605.2K | $14.7M | ||
| Q3 24 | $-6.2M | $13.1M | ||
| Q2 24 | — | $12.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 46.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 39.4% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 41.5% | ||
| Q3 25 | 9.3% | 40.5% | ||
| Q2 25 | — | 28.5% | ||
| Q1 25 | 1.5% | 10.3% | ||
| Q4 24 | 14.5% | 38.7% | ||
| Q3 24 | 2.5% | 35.2% | ||
| Q2 24 | — | 34.7% |
| Q1 26 | — | 34.0% | ||
| Q4 25 | — | 33.1% | ||
| Q3 25 | -9.6% | 32.4% | ||
| Q2 25 | — | 22.6% | ||
| Q1 25 | -2.6% | 12.2% | ||
| Q4 24 | 0.6% | 30.8% | ||
| Q3 24 | -6.6% | 29.1% | ||
| Q2 24 | — | 28.0% |
| Q1 26 | — | $1.29 | ||
| Q4 25 | — | $1.33 | ||
| Q3 25 | $-0.12 | $1.25 | ||
| Q2 25 | — | $0.83 | ||
| Q1 25 | $-0.02 | $0.43 | ||
| Q4 24 | $0.00 | $1.00 | ||
| Q3 24 | $-0.10 | $0.90 | ||
| Q2 24 | — | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.5M | — |
| Total DebtLower is stronger | — | $514.4M |
| Stockholders' EquityBook value | $288.3M | $710.0M |
| Total Assets | $734.9M | $7.0B |
| Debt / EquityLower = less leverage | — | 0.72× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $15.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $38.5M | — | ||
| Q4 24 | $29.2M | — | ||
| Q3 24 | $32.3M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $514.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $710.0M | ||
| Q4 25 | — | $696.6M | ||
| Q3 25 | $288.3M | $676.4M | ||
| Q2 25 | — | $652.1M | ||
| Q1 25 | $345.0M | $640.1M | ||
| Q4 24 | $346.3M | $531.2M | ||
| Q3 24 | $346.0M | $529.9M | ||
| Q2 24 | — | $508.3M |
| Q1 26 | — | $7.0B | ||
| Q4 25 | — | $7.0B | ||
| Q3 25 | $734.9M | $7.0B | ||
| Q2 25 | — | $6.9B | ||
| Q1 25 | $798.2M | $7.0B | ||
| Q4 24 | $835.2M | $5.8B | ||
| Q3 24 | $827.3M | $5.7B | ||
| Q2 24 | — | $5.7B |
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $14.4M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $63.9M | ||
| Q3 25 | $14.4M | $36.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | $23.3M | $1.0M | ||
| Q4 24 | $-5.4M | $60.9M | ||
| Q3 24 | $5.2M | $-14.5M | ||
| Q2 24 | — | $14.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $58.2M | ||
| Q3 25 | — | $35.4M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-727.0K | ||
| Q4 24 | — | $55.4M | ||
| Q3 24 | — | $-16.2M | ||
| Q2 24 | — | $13.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 85.5% | ||
| Q3 25 | — | 54.1% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | -1.2% | ||
| Q4 24 | — | 116.4% | ||
| Q3 24 | — | -36.0% | ||
| Q2 24 | — | 30.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.4% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.83× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | -8.85× | 4.15× | ||
| Q3 24 | — | -1.11× | ||
| Q2 24 | — | 1.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIOX
Segment breakdown not available.
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
